



CO. OF PAPERS
ORIGINALLY FILED

RECEIVED
SEP 13 2002

TECH CENTER 1600/2900

Application No.: 09/803578

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Sequences on page 14 do not have SEQ ID Nos.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



COPY OF PAPERS
ORIGINALLY FILED

PATENT
Attorney Docket No. 218122
DHHS Ref. E323-00/0

#8
done
9/25/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hwu et al.

Application No. 09/803,578

Filed: March 9, 2001

For: ACTIVATED DUAL SPECIFICITY
LYMPHOCYTES AND THEIR
METHODS OF USE

Group Art Unit: 1632

Examiner: Wilson, M.

RECEIVED

SEP 13 2002

TECH CENTER 1600/2900

SUBMISSION OF SEQUENCE LISTING

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with the requirements of 37 CFR 1.821-1.825, a sequence listing is being submitted. Applicants request that the sequence listing be made part of the application. The sequence listing is in the form of both a paper copy and a computer-readable copy on a computer diskette. The undersigned hereby verifies that the content of the paper copy and the computer-readable copy, as concurrently being submitted, are the same and do not introduce new matter.

Respectfully submitted,

Carol Larcher, Reg. No. 35,243
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: September 4, 2002

In re: Application of Hwu et al.
U.S. Application No. 09/803,578

CERTIFICATE OF MAILING

I hereby certify that this SUBMISSION OF SEQUENCE LISTING (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date: 9-4-02 Catherine M. Cioffi